In the weeks around the 2026 annual meeting of the American Society of Clinical Oncology, my phone kept buzzing with alerts about GLP-1 drugs and cancer. The headlines were everywhere—from NPR and The Washington Post to Substack and heated exchanges on social media—all circling the same claim: Ozempic might lower the risk of cancer.
This article was originally published by MedicalXpress. For more details, images, and references:
Read Full Original Article ↗